Intrigue Over Conatus Pharmaceuticals’ (CNAT) Liver-Disease Drug; Jefferies Foresees Potential In Oclaro (OCLR)


Shares of Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) climbed more than 10% in after-hours trading Monday as the biotechnology company said that four abstracts were accepted for presentation at the upcoming American Association for the Study of Liver Diseases (AASLD) annual meeting – November 11-15, 2016 – outlining clinical and preclinical data with its chronic liver disease drug Emricasan.

CNAT stock finished the regular session in negative territory by 2.00% (or -$0.04) at $1.96 with a total volume of 218,230 shares traded

Conatus Pharmaceuticals, which focuses on the development and commercialization of novel medicines to treat liver diseases, has 22.09M Shares Outstanding and CNAT stock 52-wek range is from $1.40 to $4.62 per share. At close on Monday, the company had a Market Capitalization of $43.07M



Oclaro, Inc. (Nasdaq:OCLR) shares surged to touch the $8.86 mark during Monday’s trading session after analysts at Jefferies initiated coverage on the company’s stock with a Buy rating and a price target of $11.25

OCLR stock closed at $8.72, up $0.17 (or +1.99%) and 3.20M of its shares changed hands during the day, representing a decrease in activity versus its average volume (3m) of 4.12M

Oclaro, a provider of optical components, modules and subsystems for the core optical transport, service provider, enterprise and data center markets, has 162.94M Shares Outstanding, Market Capitalization (intraday) of $1.42B and OCLR stock one-year range is between $2.28 and $9.34 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at